https://www.radcliffeckm.com/news/semaglutide-may-protect-kidney-function-individuals-overweight-or-obesity-and-cardiovascular 2025-04-07T10:28:06+01:00 0.5 https://www.radcliffeckm.com/news/aha-24-palisade-trial-shows-promise-patients-familial-chylomicronemia-syndrome 2025-03-21T10:04:56+00:00 0.5 https://www.radcliffeckm.com/news/bproad-promising-results-intensive-blood-pressure-control-type-2-diabetes-patients 2025-03-21T10:02:08+00:00 0.5 https://www.radcliffeckm.com/news/serum-uric-acid-independent-predictor-non-alcoholic-fatty-liver-disease-non-obese-young-adults 2025-03-21T10:07:13+00:00 0.5 https://www.radcliffeckm.com/news/liver-disease-efruxifermin-showed-39-cirrhosis-reversal-mash-patients-phase-2b-symmetry-study 2025-03-21T10:05:35+00:00 0.5 https://www.radcliffeckm.com/news/glp-1-receptor-agonists-reduce-risks-dementia-cardiovascular-disease-and-psychiatric-disorders 2025-03-21T09:48:36+00:00 0.5 https://www.radcliffeckm.com/news/study-finds-multimorbidity-dramatically-increases-mortality-risk-heart-failure-patients-mildly 2026-04-02T06:00:45+01:00 0.5 https://www.radcliffeckm.com/news/sodium-glucose-cotransporter-2-sglt2-inhibitors-offer-enhanced-kidney-protection-especially 2025-07-21T15:05:59+01:00 0.5 https://www.radcliffeckm.com/news/semaglutide-24mg-achieves-63-mash-resolution-phase-3-essence-trial 2025-07-21T15:04:03+01:00 0.5 https://www.radcliffeckm.com/news/absence-five-key-risk-factors-50-adds-over-decade-life 2025-07-16T11:17:29+01:00 0.5 https://www.radcliffeckm.com/news/increased-systolic-blood-pressure-variability-over-time-linked-higher-risk-cvd-ckd-and-death 2026-04-02T06:00:45+01:00 0.5 https://www.radcliffeckm.com/news/total-apob-and-lpa-count-deemed-superior-cad-risk-assessment 2025-07-16T11:56:44+01:00 0.5 https://www.radcliffeckm.com/news/new-multi-ancestry-polygenic-score-improves-bmi-and-obesity-prediction-across-lifespan 2025-07-28T15:14:58+01:00 0.5 https://www.radcliffeckm.com/news/tirzepatide-benefits-hfpef-consistent-across-obesity-levels-summit-analysis-shows 2026-04-02T06:00:45+01:00 0.5 https://www.radcliffeckm.com/news/semaglutide-modulates-key-pathways-resolve-mash-proteomic-analysis-reveals 2025-07-28T16:02:22+01:00 0.5 https://www.radcliffeckm.com/news/east-afnet-4-early-rhythm-control-effective-af-patients-obesity-and-diabetes 2025-08-05T12:02:15+01:00 0.5 https://www.radcliffeckm.com/news/multimodal-ai-model-offers-deeper-insight-glycaemic-risk-hba1c-alone 2025-08-05T15:30:24+01:00 0.5 https://www.radcliffeckm.com/news/update-trial-minimally-processed-diet-superior-weight-loss-within-healthy-eating-guidelines 2025-08-05T16:09:57+01:00 0.5 https://www.radcliffeckm.com/news/dash-diet-tailored-diabetes-significantly-improves-glycaemic-control 2025-08-07T13:27:58+01:00 0.5 https://www.radcliffeckm.com/news/surmount-1-analysis-tirzepatide-effective-common-genetic-obesity-subtype 2025-08-29T09:24:17+01:00 0.5 https://www.radcliffeckm.com/news/intensive-blood-pressure-control-shows-net-clinical-benefit-despite-increased-adverse-events 2026-03-10T16:00:46+00:00 0.5 https://www.radcliffeckm.com/news/statins-reduce-mortality-and-cvd-type-1-diabetes-primary-prevention 2025-09-15T12:01:33+01:00 0.5 https://www.radcliffeckm.com/news/nhs-diabetes-prevention-programme-linked-lower-incidence-multiple-long-term-conditions 2025-09-25T10:30:05+01:00 0.5 https://www.radcliffeckm.com/news/metabolic-surgery-superior-glp-1-ras-long-term-outcomes-patients-diabetes-and-obesity 2025-09-17T16:36:55+01:00 0.5 https://www.radcliffeckm.com/news/tirzepatide-shows-significant-glycaemic-and-bmi-improvements-youth-type-2-diabetes 2025-09-29T13:00:28+01:00 0.5 https://www.radcliffeckm.com/news/intensive-bp-lowering-improves-retinal-microvasculature 2025-10-22T11:47:04+01:00 0.5 https://www.radcliffeckm.com/news/mc4r-deficiency-obesity-lower-cvd-risk 2025-10-22T12:00:43+01:00 0.5 https://www.radcliffeckm.com/news/semaglutide-improves-pad-outcomes-regardless-sex 2025-11-12T14:41:50+00:00 0.5 https://www.radcliffeckm.com/news/albuminuria-change-validated-ckd-surrogate-endpoint 2025-11-12T15:03:02+00:00 0.5 https://www.radcliffeckm.com/news/pemvidutide-mash-impact-trial-24-week-results 2025-11-12T15:37:31+00:00 0.5 https://www.radcliffeckm.com/news/tirzepatide-and-semaglutide-comparable-cv-outcomes 2025-11-12T16:11:48+00:00 0.5 https://www.radcliffeckm.com/news/eloralintide-shows-significant-weight-loss-phase-2-trial 2025-11-12T16:17:23+00:00 0.5 https://www.radcliffeckm.com/news/balcinrenone-plus-dapagliflozin-cuts-albuminuria-ckd 2025-11-12T16:39:03+00:00 0.5 https://www.radcliffeckm.com/news/fish-oil-cuts-cv-events-haemodialysis-patients 2025-11-12T16:42:35+00:00 0.5 https://www.radcliffeckm.com/news/olezarsen-cuts-triglycerides-and-pancreatitis-risk 2025-11-13T10:38:45+00:00 0.5 https://www.radcliffeckm.com/news/preventive-care-strategy-cuts-aki-risk-after-major-surgery 2025-11-24T15:36:37+00:00 0.5 https://www.radcliffeckm.com/news/egfr-decline-precedes-hfref-hospitalisation-year 2025-11-24T16:23:23+00:00 0.5 https://www.radcliffeckm.com/news/waist-height-ratio-outperforms-bmi-hfpef-risk 2026-04-02T06:00:45+01:00 0.5 https://www.radcliffeckm.com/news/finerenone-cuts-uacr-ckd-type-1-diabetes 2025-11-24T16:43:51+00:00 0.5 https://www.radcliffeckm.com/news/lpa-and-il-6-independently-predict-ascvd-risk 2025-11-24T17:08:43+00:00 0.5 https://www.radcliffeckm.com/news/oral-orforglipron-reduces-weight-obesity-and-t2d 2025-11-24T17:21:51+00:00 0.5 https://www.radcliffeckm.com/news/liraglutide-slows-cognitive-decline-alzheimers-trial 2025-12-03T12:44:06+00:00 0.5 https://www.radcliffeckm.com/news/body-fat-pattern-predicts-cv-ageing-differently-sexes 2025-12-10T09:32:09+00:00 0.5 https://www.radcliffeckm.com/news/tirzepatide-noninferior-dulaglutide-cv-events 2025-12-23T09:34:04+00:00 0.5 https://www.radcliffeckm.com/news/zeus-trial-il-6-inhibition-ascvd-and-ckd 2025-12-23T09:47:59+00:00 0.5 https://www.radcliffeckm.com/news/primary-care-process-curbs-population-weight-gain 2025-12-23T09:59:49+00:00 0.5 https://www.radcliffeckm.com/news/oral-orforglipron-aids-weight-loss-type-2-diabetes 2025-12-23T10:02:41+00:00 0.5 https://www.radcliffeckm.com/news/metabolome-informed-bmi-better-predicts-cvrm-risk 2026-01-06T09:28:33+00:00 0.5 https://www.radcliffeckm.com/news/high-dose-flu-vaccine-reduces-hospitalisation-ckd 2026-03-05T14:55:05+00:00 0.5 https://www.radcliffeckm.com/news/global-economic-burden-diabetes-exceed-10-trillion 2026-01-06T09:35:01+00:00 0.5 https://www.radcliffeckm.com/news/select-semaglutide-reduces-hospital-admissions 2026-01-06T09:37:42+00:00 0.5 https://www.radcliffeckm.com/news/tirzepatide-cuts-cardiometabolic-risk-osa-obesity 2026-02-23T13:55:31+00:00 0.5 https://www.radcliffeckm.com/news/metabolite-profile-predicts-future-type-2-diabetes-risk 2026-01-21T09:58:19+00:00 0.5 https://www.radcliffeckm.com/news/study-6-10-us-adults-eligible-ckm-drugs 2026-03-05T14:10:55+00:00 0.5 https://www.radcliffeckm.com/news/bi-764198-reduces-proteinuria-fsgs-phase-2-trial 2026-02-03T15:52:11+00:00 0.5 https://www.radcliffeckm.com/news/ticagrelor-fails-noninferiority-prasugrel-tuxedo-2 2026-03-03T08:26:09+00:00 0.5 https://www.radcliffeckm.com/news/obicetrapib-lowers-ldl-c-familial-hypercholesterolemia 2026-03-03T11:38:57+00:00 0.5 https://www.radcliffeckm.com/news/pelacarsen-cuts-lipoprotein-apheresis-need-cvd 2026-03-04T09:26:28+00:00 0.5 https://www.radcliffeckm.com/news/empagliflozin-and-finerenone-hyperkalemia-risk-ckd 2026-03-05T17:59:44+00:00 0.5 https://www.radcliffeckm.com/news/oral-orforglipron-superior-semaglutide-t2d-control 2026-03-10T08:57:30+00:00 0.5 https://www.radcliffeckm.com/news/higher-arr-linked-af-and-stroke-risk-older-adults 2026-03-12T17:31:28+00:00 0.5 https://www.radcliffeckm.com/news/semaglutide-may-aid-vascular-repair-high-risk-patients 2026-03-19T09:17:10+00:00 0.5 https://www.radcliffeckm.com/news/aldosteronism-linked-af-and-stroke-risk-older-adults 2026-03-19T09:23:49+00:00 0.5 https://www.radcliffeckm.com/news/glp-1ras-cut-cardiorenal-events-type-1-diabetes 2026-03-27T08:26:08+00:00 0.5 https://www.radcliffeckm.com/news/soul-oral-semaglutide-aids-cv-risk-t2d 2026-03-27T08:46:33+00:00 0.5 https://www.radcliffeckm.com/news/hscrp-improves-cv-risk-prediction-primary-prevention 2026-04-15T16:20:52+01:00 0.5 https://www.radcliffeckm.com/news/ez-pave-lower-ldl-c-target-reduces-cv-events 2026-04-15T16:35:25+01:00 0.5